Acura Pharmaceuticals to Present at the 26th Annual ROTH Conference

PALATINE, IL--(Marketwired - Mar 5, 2014) -  Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, today announced that Bob Jones, President and Chief Executive Officer, will present at the 26^th Annual ROTH Capital Conference on Tuesday, March 11, 2014 at 4:00 p.m. Pacific Time. The conference is being held at the Ritz-Carlton Laguna Niguel in Dana Point, California.

The presentation will be webcast live and may be accessed by visiting Acura's website at www.acurapharm.com. A replay of the webcast will be available for 90 days.

About Acura Pharmaceuticals
Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary AVERSION® and IMPEDE® Technologies. AVERSION® contains polymers that cause the drug to gel when dissolved; it also contains compounds that irritate the nasal passages. IMPEDE® is designed to disrupt the processing of pseudoephedrine from tablets into methamphetamine.

In June 2011, the U.S. Food and Drug Administration approved OXECTA® (oxycodone HC1 tablets) which incorporates the AVERSION® technology. The Company has a development pipeline of additional AVERSION® technology products containing other opioids. 

The trademark OXECTA® is owned by Pfizer Inc.